Lipid-Lowering Efficacy and Adverse Events of CETP Inhibitor Combination Therapy: A Systematic Review and Network Meta-Analysis. [PDF]
Guo P, Yu X, Wei X, Xiong X, Jiang J.
europepmc +1 more source
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. [PDF]
Nicholls SJ +8 more
europepmc +1 more source
Cholesterol-Lowering Treatment Blocks Epithelial-Mesenchymal Transition (EMT) Associated Invasiveness and Drug Resistance in Breast and Colorectal Adenocarcinoma Models. [PDF]
Perumal S, Abdulla N, Aronson R, Kaur M.
europepmc +1 more source
Effects of evolocumab on lipid profile and circulating endothelial biomarkers in patients undergoing primary percutaneous coronary intervention. [PDF]
Jiang W +4 more
europepmc +1 more source
Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis. [PDF]
Masson W +4 more
europepmc +1 more source
Combined Use of Statin and PCSK9 Inhibitor in a Pregnant Woman with Possible Familial Hypercholesterolemia and Coronary Artery Stenosis. [PDF]
Shimizu Y +11 more
europepmc +1 more source
The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta-Analysis and Trial Sequential Analysis. [PDF]
Wang S, Li C, Fan D.
europepmc +1 more source
Sitosterolemia due to compound heterozygous mutations in ABCG5: a case report. [PDF]
Wu LL +7 more
europepmc +1 more source
Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome. [PDF]
Jukema JW +14 more
europepmc +1 more source
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity-Matched Cohort Study. [PDF]
Nardi Agmon I +10 more
europepmc +1 more source

